$ENTO
Entero Therapeutics Inc Stock $ento

$ento Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-Q Financial Statement

#000165495421009097 Filed on August 16, 2021

Income Statement

Concept	2021 Q3	2021 Q2	2020 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.021M	$3.628M	$2.696M
YoY Change	214.76%	178.97%	-650.22%
% of Gross Profit
Research & Development	$24.38M	$5.648M	$14.68M
YoY Change	1261.31%	418.54%	811.8%
% of Gross Profit
Depreciation & Amortization	$138.3K	$2.000K	$143.1K
YoY Change	-1.29%	-77.78%	2.24%
% of Gross Profit
Operating Expenses	$30.40M	$9.277M	$17.40M
YoY Change	718.97%	751.73%	1439.71%
Operating Profit	-$30.40M	-$9.277M
YoY Change		287.55%
Interest Expense	-$740.00	$2.954K	-$1.720K
YoY Change	-99.94%	-99.87%	-98.93%
% of Operating Profit
Other Income/Expense, Net	-$570.00	-$2.056K
YoY Change		-99.91%
Pretax Income	-$30.40M	-$9.279M	-$17.40M
YoY Change	472.1%	97.6%	1259.41%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$30.40M	-$9.279M	-$17.40M
YoY Change	472.1%	97.6%	1259.41%
Net Earnings / Revenue
Basic Earnings Per Share	-$98.00	-$1.63
Diluted Earnings Per Share	-$97.63M	-$1.63	-$5.750M
COMMON SHARES
Basic Shares Outstanding	93.26M shares	7.812M
Diluted Shares Outstanding	311.4K	7.812M

Balance Sheet

Concept	2021 Q3	2021 Q2	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.211M	$8.074M	$6.062M
YoY Change	-36.57%	719.79%	3267.86%
Cash & Equivalents	$7.211M	$8.074M	$6.062M
Short-Term Investments
Other Short-Term Assets	$291.8K	$540.8K	$1.256M
YoY Change	96.39%	5.34%	109.36%
Inventory
Prepaid Expenses		$540.8K	$1.256M
Receivables		$0.00	$551.5K
Other Receivables
Total Short-Term Assets	$7.502M	$8.615M	$7.870M
YoY Change	-34.98%	438.15%	130.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$448.9K	$89.24K	$18.33K
YoY Change	183.62%	-53.42%	-88.54%
Goodwill		$1.991M	$2.054M
YoY Change			8.87%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$44.03K	$69.60K	$5.036M
YoY Change	-3.95%	92.96%	12489.36%
Total Long-Term Assets	$4.922M	$5.162M	$5.054M
YoY Change	-5.06%	-1.89%	-7.94%
TOTAL ASSETS
Total Short-Term Assets	$7.502M	$8.615M	$7.870M
Total Long-Term Assets	$4.922M	$5.162M	$5.054M
Total Assets	$12.42M	$13.78M	$12.92M
YoY Change	-25.7%	100.78%	45.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.45M	$4.644M	$1.686M
YoY Change	1197.25%	286.88%	-23.73%
Accrued Expenses	$229.9K	$194.0K	$127.0K
YoY Change	-32.01%	-3.56%	-15.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$139.6K	$552.4K
YoY Change		-97.41%	-63.66%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$19.10M	$6.454M	$15.55M
YoY Change	627.47%	-15.25%	262.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$295.7K	$285.8K	$19.12K
YoY Change	839.59%	554.95%
Total Long-Term Liabilities	$295.7K	$285.8K	$19.12K
YoY Change	839.59%	554.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.10M	$6.454M	$15.55M
Total Long-Term Liabilities	$295.7K	$285.8K	$19.12K
Total Liabilities	$19.39M	$6.740M	$15.56M
YoY Change	629.98%	-12.0%	262.81%
SHAREHOLDERS EQUITY
Retained Earnings		-$112.3M	-$95.37M
YoY Change
Common Stock		$8.260K	$312.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.970M	$7.037M	-$2.641M
YoY Change
Total Liabilities & Shareholders Equity	$12.42M	$13.78M	$12.92M
YoY Change	-25.7%	100.78%	45.21%

Cashflow Statement

Concept	2021 Q3	2021 Q2	2020 Q4
OPERATING ACTIVITIES
Net Income	-$30.40M	-$9.279M	-$17.40M
YoY Change	472.1%	97.6%	1259.41%
Depreciation, Depletion And Amortization	$138.3K	$2.000K	$143.1K
YoY Change	-1.29%	-77.78%	2.24%
Cash From Operating Activities	-$15.73M	-$5.623M	-$5.890M
YoY Change	483.25%	113.41%	82.92%
INVESTING ACTIVITIES
Capital Expenditures	$2.480K	-$73.93K	-$1.360K
YoY Change		2530.96%
Acquisitions
YoY Change
Other Investing Activities	-$10.25M		$91.52K
YoY Change
Cash From Investing Activities	-$10.25M	-$73.93K	$90.16K
YoY Change		2530.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$264.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	25.11M	1.782M	552.4K
YoY Change	92.25%	-48.1%	-69.98%
NET CHANGE
Cash From Operating Activities	-15.73M	-5.623M	-5.890M
Cash From Investing Activities	-10.25M	-73.93K	90.16K
Cash From Financing Activities	25.11M	1.782M	552.4K
Net Change In Cash	-868.8K	-3.915M	-5.247M
YoY Change	-108.38%	-591.76%	280.25%
FREE CASH FLOW
Cash From Operating Activities	-$15.73M	-$5.623M	-$5.890M
Capital Expenditures	$2.480K	-$73.93K	-$1.360K
Free Cash Flow	-$15.73M	-$5.549M	-$5.889M
YoY Change	483.34%	110.83%	82.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	93261897	shares
CY2021Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	8074491	USD
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	6062141	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	551489	USD
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	540786	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1256154	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	8615277	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	7869784	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13776799	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	89243	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18329	USD
CY2021Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	2615762	USD
CY2020Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	2879536	USD
CY2021Q2	us-gaap	Goodwill Goodwill	1991287	USD
CY2020Q4	us-gaap	Goodwill Goodwill	2054048	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	395634	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	74238	USD
CY2021Q2	us-gaap	Deposits Assets DepositsAssets	69596	USD
CY2020Q4	us-gaap	Deposits Assets DepositsAssets	27920	USD
CY2021Q2	us-gaap	Other Assets OtherAssets	5072279	USD
CY2020Q4	us-gaap	Other Assets OtherAssets	5035742	USD
CY2021Q2	us-gaap	Assets Assets	13776799	USD
CY2020Q4	us-gaap	Assets Assets	12923855	USD
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4643885	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1685603	USD
CY2021Q2	azrx	License Agreement Payable Current LicenseAgreementPayableCurrent	1250000	USD
CY2020Q4	azrx	License Agreement Payable Current LicenseAgreementPayableCurrent	13250000	USD
CY2021Q2	us-gaap	Dividends Payable Current DividendsPayableCurrent	231043	USD
CY2020Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	0	USD
CY2021Q2	us-gaap	Notes Payable Current NotesPayableCurrent	139569	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	552405	USD
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	189625	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	57417	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6454122	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15545425	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	285753	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	19123	USD
CY2021Q2	us-gaap	Liabilities Liabilities	6739875	USD
CY2020Q4	us-gaap	Liabilities Liabilities	15564548	USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	82585075	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31150309	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	8260	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	3115	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	120584938	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	93834936	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-112330771	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95366198	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1225503	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1112546	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7036924	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-2640693	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12923855	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5647798	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1089177	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8163825	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2642537	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3629090	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1304527	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9326604	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2679618	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9276888	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2393704	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17490429	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5322155	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	2954	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	2302174	USD
	us-gaap	Interest Expense InterestExpense	8098	USD
	us-gaap	Interest Expense InterestExpense	4635013	USD
CY2021Q2	us-gaap	Other Income OtherIncome	898	USD
CY2020Q2	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Income OtherIncome	1601	USD
	us-gaap	Other Income OtherIncome	0	USD
CY2020Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2056	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2302174	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	525856	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4635013	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-9278944	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-4695878	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-16964573	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-9957168	USD
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	21840	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-163719	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-112957	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-6225	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9257104	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4859597	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17077530	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9963393	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-9278944	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4695878	USD
	us-gaap	Net Income Loss NetIncomeLoss	-16964573	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9957168	USD
CY2021Q2	azrx	Deemed Dividends Preferred Stock Issuances DeemedDividendsPreferredStockIssuances	0	USD
	azrx	Deemed Dividends Preferred Stock Issuances DeemedDividendsPreferredStockIssuances	4507125	USD
CY2020Q2	azrx	Deemed Dividends Preferred Stock Issuances DeemedDividendsPreferredStockIssuances	0	USD
CY2021Q2	azrx	Deemed Dividend On Preferred Stock Exchanges DeemedDividendOnPreferredStockExchanges	3424205	USD
	azrx	Deemed Dividends Preferred Stock Issuances DeemedDividendsPreferredStockIssuances	0	USD
CY2020Q2	azrx	Deemed Dividend On Preferred Stock Exchanges DeemedDividendOnPreferredStockExchanges	0	USD
CY2021Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	26661	USD
	azrx	Deemed Dividend On Preferred Stock Exchanges DeemedDividendOnPreferredStockExchanges	0	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	231043	USD
CY2020Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12729810	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4695878	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42710994	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9957168	USD
CY2021Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	78124399	shares
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28016478	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	66799183	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27479140	shares
CY2021Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.64
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	3041123	USD
CY2020Q2	azrx	Common Stock Issued To Lincoln Park For Equity Purchase Agreement Amount CommonStockIssuedToLincolnParkForEquityPurchaseAgreementAmount	844348	USD
CY2020Q2	us-gaap	Share Based Compensation ShareBasedCompensation	176676	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-163719	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4695878	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-797450	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	4617244	USD
	azrx	Common Stock Issued To Settle Accounts Payable Amount CommonStockIssuedToSettleAccountsPayableAmount	131137	USD
	azrx	Common Stock Issued To Consultants Amount CommonStockIssuedToConsultantsAmount	87105	USD
	azrx	Common Stock Issued To Lincoln Park For Equity Purchase Agreement Amount CommonStockIssuedToLincolnParkForEquityPurchaseAgreementAmount	988348	USD
	us-gaap	Net Income Loss NetIncomeLoss	-16964573	USD
	azrx	Warrants Issued In Association With Convertible Debt Issuances WarrantsIssuedInAssociationWithConvertibleDebtIssuances	1252558	USD
	azrx	Beneficial Conversion Feature On Convertible Debt Issuances BeneficialConversionFeatureOnConvertibleDebtIssuances	1838422	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	251129	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-6225	USD
	us-gaap	Accretion Expense AccretionExpense	4203182	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-36033	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	551489	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	2548659	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	715368	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7036924	USD
	us-gaap	Net Income Loss NetIncomeLoss	-16964573	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9957168	USD
	us-gaap	Depreciation Depreciation	3014	USD
	us-gaap	Depreciation Depreciation	18368	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	263774	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9957168	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-797450	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	14401687	USD
CY2021Q2	azrx	Issuance Of Series C Preferred Stock Upon Exchange Of Series B Preferred Stock Amount IssuanceOfSeriesCPreferredStockUponExchangeOfSeriesBPreferredStockAmount	-422	USD
CY2021Q2	azrx	Warrants Issued In Connection With Exchange Of Series B Preferred Stock WarrantsIssuedInConnectionWithExchangeOfSeriesBPreferredStock	3424626	USD
CY2021Q2	azrx	Deemed Dividend Related To Exchange Of Series B Preferred Stock DeemedDividendRelatedToExchangeOfSeriesBPreferredStock	-3424205	USD
CY2021Q2	azrx	Dividends On Preferred Stock DividendsOnPreferredStock	-26661	USD
CY2021Q2	azrx	Common Stock And Pre Funded Warrants Issued Upon Conversion Of Series C Preferred Stock Amount CommonStockAndPreFundedWarrantsIssuedUponConversionOfSeriesCPreferredStockAmount	0	USD
CY2021Q2	azrx	Issuance Of Common Stock At The Market For Cash Net Of Offering Costs Amount IssuanceOfCommonStockAtTheMarketForCashNetOfOfferingCostsAmount	1174348	USD
CY2021Q2	azrx	Common Stock Issued Upon Exercise Of Warrants Amount CommonStockIssuedUponExerciseOfWarrantsAmount	282788	USD
CY2021Q2	azrx	Common Stock And Warrants Issued To Consultants Amount CommonStockAndWarrantsIssuedToConsultantsAmount	147811	USD
CY2021Q2	azrx	Settlement With Former Placement Agent SettlementWithFormerPlacementAgent	0	USD
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	314056	USD
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	21840	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-9278944	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7036924	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-2640693	USD
	azrx	Issuance Of Series C Preferred Stock And Warrants For Cash Net Of Offering Costs Amount IssuanceOfSeriesCPreferredStockAndWarrantsForCashNetOfOfferingCostsAmount	7105168	USD
	azrx	Issuance Of Series C Preferred Stock For License Acquired Amount IssuanceOfSeriesCPreferredStockForLicenseAcquiredAmount	2467649	USD
	azrx	Beneficial Conversion Feature Of Series C Preferred Stock BeneficialConversionFeatureOfSeriesCPreferredStock	4507125	USD
	azrx	Dividends Series C Preferred Stock DividendsSeriesCPreferredStock	-4507125	USD
	azrx	Issuance Of Series C Preferred Stock Upon Exchange Of Series B Preferred Stock Amount IssuanceOfSeriesCPreferredStockUponExchangeOfSeriesBPreferredStockAmount	-1430	USD
	azrx	Warrants Issued In Connection With Exchange Of Series B Preferred Stock WarrantsIssuedInConnectionWithExchangeOfSeriesBPreferredStock	21009683	USD
	azrx	Deemed Dividend Related To Exchange Of Series B Preferred Stock DeemedDividendRelatedToExchangeOfSeriesBPreferredStock	-21008253	USD
	azrx	Common Stock Issued Upon Conversion Of Series B Preferred Stock Amount CommonStockIssuedUponConversionOfSeriesBPreferredStockAmount	0	USD
	azrx	Dividends On Preferred Stock DividendsOnPreferredStock	-231043	USD
	azrx	Common Stock And Pre Funded Warrants Issued Upon Conversion Of Series C Preferred Stock Amount CommonStockAndPreFundedWarrantsIssuedUponConversionOfSeriesCPreferredStockAmount	0	USD
	azrx	Issuance Of Common Stock Pre Funded Warrants And Warrants For Cash Net Of Offering Costs Amount IssuanceOfCommonStockPreFundedWarrantsAndWarrantsForCashNetOfOfferingCostsAmount	9059290	USD
	azrx	Issuance Of Common Stock At The Market For Cash Net Of Offering Costs Amount IssuanceOfCommonStockAtTheMarketForCashNetOfOfferingCostsAmount	1174348	USD
	azrx	Common Stock Issued Upon Exercise Of Warrants Amount CommonStockIssuedUponExerciseOfWarrantsAmount	4906630	USD
	azrx	Common Stock And Warrants Issued To Consultants Amount CommonStockAndWarrantsIssuedToConsultantsAmount	1092310	USD
	azrx	Settlement With Former Placement Agent Amount SettlementWithFormerPlacementAgentAmount	94499	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1086296	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-112957	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	263774	USD
	azrx	Non Cash Lease Expense NonCashLeaseExpense	-4855	USD
	azrx	Non Cash Lease Expense NonCashLeaseExpense	-6065	USD
	azrx	Common Stock Issued To Settle Accounts Payable CommonStockIssuedToSettleAccountsPayable	0	USD
	azrx	Common Stock Issued To Settle Accounts Payable CommonStockIssuedToSettleAccountsPayable	131137	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	532353	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1086296	USD
	azrx	Restricted Stock Granted To Employees And Directors RestrictedStockGrantedToEmployeesAndDirectors	0	USD
	azrx	Restricted Stock Granted To Employees And Directors RestrictedStockGrantedToEmployeesAndDirectors	21003	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1186809	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	87105	USD
	azrx	Accreted Interest On Convertible Debt AccretedInterestOnConvertibleDebt	0	USD
	azrx	Accreted Interest On Convertible Debt AccretedInterestOnConvertibleDebt	319196	USD
	us-gaap	Accretion Expense AccretionExpense	0	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	274019	USD
	azrx	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-316541	USD
	azrx	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-108447	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-41676	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	5000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2958282	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-571728	USD
	azrx	Accrued Dividends Payable AccruedDividendsPayable	0	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	398838	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	135210	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10696128	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2634733	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	73928	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2808	USD
	azrx	Payments For License Agreement PaymentsForLicenseAgreement	9000000	USD
	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-192071	USD
	azrx	Deemed Dividend On Preferred Stock Issuances DeemedDividendOnPreferredStockIssuances	0	USD
	azrx	Accrued Dividends Payable AccruedDividendsPayable	0	USD
	azrx	Payments For License Agreement PaymentsForLicenseAgreement	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9073928	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2808	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	179418	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	7105168	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10233638	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	988348	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4906630	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3227002	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	450000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	412836	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	511173	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21832600	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3433595	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2062544	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	796054	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-50194	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	13100	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6062141	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	175796	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8074491	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	984950	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	104153	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	azrx	Deemed Dividend On Preferred Stock Issuances DeemedDividendOnPreferredStockIssuances	-4507125	USD
	azrx	Deemed Dividend On Preferred Stock Exchanges DeemedDividendOnPreferredStockExchanges	0	USD
	azrx	Accrued Dividends On Preferred Stock AccruedDividendsOnPreferredStock	-231043	USD
	azrx	Accrued Dividends On Preferred Stock AccruedDividendsOnPreferredStock	0	USD
	azrx	Issuance Of Preferred Stock To Settle Liability Related To License Agreement IssuanceOfPreferredStockToSettleLiabilityRelatedToLicenseAgreement	2467649	USD
	azrx	Issuance Of Preferred Stock To Settle Liability Related To License Agreement IssuanceOfPreferredStockToSettleLiabilityRelatedToLicenseAgreement	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying unaudited consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill, intangible assets, and contingent consideration), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. On June 30, 2021, and December 31, 2020, the Company had approximately $3.8 million and $2.7 million, respectively, in one account in the U.S. in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company mitigates its risk by maintaining the majority of its cash and equivalents with high quality financial institutions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros.</p>
CY2021Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3800000	USD
CY2020Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2700000	USD
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P7Y2M12D
	us-gaap	Business Acquisition Description Of Acquired Entity BusinessAcquisitionDescriptionOfAcquiredEntity	an asset acquisition and initial liabilities of approximately $13.3 million in connection with the license acquisition were recorded as research and development expense, because it was determined to have no alternative future uses and therefore no separate economic value, which included cash payments totaling approximately $10.3 million and the issuance of approximately $3.0 million worth of preferred stock.
CY2021Q2	azrx	Research And Development Tax Credits Receivable ResearchAndDevelopmentTaxCreditsReceivable	0	USD
CY2020Q4	azrx	Research And Development Tax Credits Receivable ResearchAndDevelopmentTaxCreditsReceivable	493906	USD
CY2021Q2	us-gaap	Other Receivables OtherReceivables	0	USD
CY2020Q4	us-gaap	Other Receivables OtherReceivables	57583	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	551489	USD
CY2021Q2	azrx	Payment Of Refundable Tax Credits PaymentOfRefundableTaxCredits	550000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	90468	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	56732	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	89243	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18329	USD
CY2021Q2	us-gaap	Depreciation Depreciation	2000	USD
CY2020Q2	us-gaap	Depreciation Depreciation	9000	USD
	azrx	Lease Hpold Expenses LeaseHpoldExpenses	29000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3800000	USD
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	132000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	132000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	264000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	264000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	263774	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	527548	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	527548	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	527548	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	527548	USD
CY2021Q2	azrx	Finite Lived Intangible Assets Amortization Expense Year Six FiniteLivedIntangibleAssetsAmortizationExpenseYearSix	241796	USD
	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.09	pure
	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	0.97
	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	3500000	USD
	us-gaap	Line Of Credit Facility Interest Rate Description LineOfCreditFacilityInterestRateDescription	The Note Warrants have an exercise price of $1.07 per share and expire five years from the date of issuance
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.18
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y8M19D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2413727	shares
CY2021Q2	azrx	Total Total	2615762	USD
CY2019Q4	us-gaap	Goodwill Goodwill	1886686	USD
CY2020	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	167362	USD
CY2020Q4	us-gaap	Goodwill Goodwill	2054048	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-62761	USD
CY2021Q2	us-gaap	Goodwill Goodwill	1991287	USD
CY2021Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4449910	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1558591	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	193975	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	127012	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4643885	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1685603	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.41
	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	70000	USD
	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	57000	USD
CY2020Q2	us-gaap	Notes Payable Current NotesPayableCurrent	113000	USD
CY2019Q1	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	2000000.0	USD
CY2019	us-gaap	Repayments Of Debt RepaymentsOfDebt	1550000	USD
CY2021Q2	us-gaap	Convertible Debt ConvertibleDebt	450000	USD
CY2021Q2	azrx	Accrued Interest Expenses AccruedInterestExpenses	104000000000	USD
CY2019Q4	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	8000000.0	USD
CY2020Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2400000	USD
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82585075	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31150309	shares
CY2021Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	264000	USD
	us-gaap	Debt Conversion Description DebtConversionDescription	the Company paid aggregate placement agent fees of approximately $277,000, which fees were based on (i) 9% of the aggregate principal amount of the Promissory Notes issued to the Note Investors introduced by the placement agent, and (ii) a non-accountable expense allowance of 1% of the gross proceeds from the Promissory Note Offering. In addition, the placement agent was issued warrants (the “Placement Agent Warrants”), to purchase an aggregate of 199,732 shares of Common Stock representing 7% of the Promissory Note Conversion Shares issuable upon conversion of the Promissory Notes issued to the Note Investors. The Placement Agent Warrants expire five years from the date of issuance. 41,495 of these Placement Agent Warrants have an exercise price of $1.21 per share and 158,237 of these Placement Agent Warrants have an exercise price of $1.42 per share
CY2020Q1	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	3500000	USD
CY2020Q1	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	1800000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	500000	USD
CY2020Q1	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	100000	USD
CY2019Q4	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	100000	USD
CY2019Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.07
CY2020Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	2300000	USD
CY2020Q2	azrx	Debt Discount Related To The Value Of The Note Warrants DebtDiscountRelatedToTheValueOfTheNoteWarrants	700000	USD
CY2020Q2	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	1100000	USD
CY2020Q2	azrx	Accrued Interest Expenses AccruedInterestExpenses	300000	USD
CY2020Q2	azrx	Accrued Interest Expenses AccruedInterestExpenses	200000	USD
CY2019Q4	azrx	Debt Instrument Unamortized Discount Accrued Interest DebtInstrumentUnamortizedDiscountAccruedInterest	-4500000	USD
	azrx	Debt Discount Related To The Value Of The Note Warrants DebtDiscountRelatedToTheValueOfTheNoteWarrants	1300000	USD
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	2200000	USD
CY2020Q2	azrx	Debt Instrument Unamortized Discount Accrued Interest DebtInstrumentUnamortizedDiscountAccruedInterest	700000	USD
CY2020Q2	azrx	Debt Instrument Unamortized Discount Accrued Interest DebtInstrumentUnamortizedDiscountAccruedInterest	300000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	118486	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	57417	USD
CY2021Q2	azrx	Other Other Liabilities Current OtherOtherLiabilitiesCurrent	71139	USD
CY2020Q4	azrx	Other Other Liabilities Current OtherOtherLiabilitiesCurrent	0	USD
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	189625	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	57417	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	285753	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19123	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	285753	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	19123	USD
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	10666668	shares
CY2021Q2	azrx	Warrant Exercise Price WarrantExercisePrice	0.80
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6000000.0	USD
CY2021Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	3400000	USD
CY2021Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	328375	shares
	azrx	Prefund Warrants Issued PrefundWarrantsIssued	9526209	shares
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	4900000	USD
	azrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P5Y4M13D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.00
	azrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2	P10Y
	azrx	Share Based Compensation Arrangement By Share Based Payment Award Options Cancellations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod	-200000	shares
	azrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Canceled Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCanceledWeightedAverageRemainingContractualTerm	P3Y3M10D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5378288	shares
CY2019Q4	azrx	Stockholders Equity Warrants Or Rights Outstanding Weighted Average Exercise Price Of Underlying Shares StockholdersEquityWarrantsOrRightsOutstandingWeightedAverageExercisePriceOfUnderlyingShares	2.53
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	2012989	shares
	azrx	Stockholders Equity Warrants Or Rights Granted In Period Weighted Average Exercise Price StockholdersEquityWarrantsOrRightsGrantedInPeriodWeightedAverageExercisePrice	1.10
	azrx	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeiture And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitureAndExpirations	30096	shares
	azrx	Stockholders Equity Warrants Or Rights Forfeited In Period Weighted Average Expiration Price StockholdersEquityWarrantsOrRightsForfeitedInPeriodWeightedAverageExpirationPrice	4.92
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7361181	shares
CY2020Q2	azrx	Stockholders Equity Warrants Or Rights Outstanding Weighted Average Exercise Price Of Underlying Shares StockholdersEquityWarrantsOrRightsOutstandingWeightedAverageExercisePriceOfUnderlyingShares	2.13
CY2020Q4	azrx	Stockholders Equity Warrants Or Rights Outstanding Weighted Average Exercise Price Of Underlying Shares StockholdersEquityWarrantsOrRightsOutstandingWeightedAverageExercisePriceOfUnderlyingShares	1.22
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	39224830	shares
	azrx	Stockholders Equity Warrants Or Rights Granted In Period Weighted Average Exercise Price StockholdersEquityWarrantsOrRightsGrantedInPeriodWeightedAverageExercisePrice	0.78
	azrx	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeiture And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitureAndExpirations	-321193	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	9526209	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	54556620	shares
CY2021Q2	azrx	Stockholders Equity Warrants Or Rights Outstanding Weighted Average Exercise Price Of Underlying Shares StockholdersEquityWarrantsOrRightsOutstandingWeightedAverageExercisePriceOfUnderlyingShares	1.02
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	54556620	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P4Y4M17D
CY2021Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	1.02
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y4M17D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.838	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.908	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0036	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0090	pure
	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	200000	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2272506	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.86
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M7D
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1084834	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.59
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y7M6D
	azrx	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	2.10
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.38
	azrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P7Y11M8D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.88
	azrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2	P10Y
	azrx	Share Based Compensation Arrangement By Share Based Payment Award Options Cancellations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod	-1339784	shares
	azrx	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	1.05
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4295191	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2021Q2	azrx	Unrecognized Stock Based Compensation Expense Others UnrecognizedStockBasedCompensationExpenseOthers	1100000	USD
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	800000	USD
CY2020Q2	azrx	Unrecognized Stock Based Compensation Expense Others UnrecognizedStockBasedCompensationExpenseOthers	900000	USD
CY2020Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	327000	USD
	azrx	Leases Expiry Description LeasesExpiryDescription	leases expire at various dates through 2026
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	57000	USD
CY2020Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	40000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	110000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	77000	USD
	azrx	Operating Lease Weighted Average Remaining Leases Term1 OperatingLeaseWeightedAverageRemainingLeasesTerm1	P4Y6M
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0686	pure
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	61642	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	104629	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	83691	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	86202	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	88788	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	60593	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	485545	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	404239	USD
CY2021Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27300000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26100000	USD
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27300000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26100000	USD
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1200000	USD
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-400000	USD
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	65100000	USD
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	22600000	USD
	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.50	pure
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	27000000.0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	23000000.0	USD
	us-gaap	Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage	0.06	pure
CY2021Q2	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	23000	USD
CY2020Q2	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	40000	USD
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	55000	USD
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	62000	USD

Files In Submission

Name	View Source	Status
0001654954-21-009097-index-headers.html	Edgar Link	pending
0001654954-21-009097-index.html	Edgar Link	pending
0001654954-21-009097.txt	Edgar Link	pending
0001654954-21-009097-xbrl.zip	Edgar Link	pending
azrx-20210630.xsd	Edgar Link	pending
azrx-20210630_cal.xml	Edgar Link	unprocessable
azrx-20210630_def.xml	Edgar Link	unprocessable
azrx-20210630_lab.xml	Edgar Link	unprocessable
azrx-20210630_pre.xml	Edgar Link	unprocessable
azrx_10q.htm	Edgar Link	pending
azrx_10q_htm.xml	Edgar Link	completed
azrx_ex311.htm	Edgar Link	pending
azrx_ex312.htm	Edgar Link	pending
azrx_ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENTO
Entero Therapeutics Inc Stock $ento

2021 Q3 Form 10-Q Financial Statement

#000165495421009097 Filed on August 16, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTO Entero Therapeutics Inc Stock $ento

2021 Q3 Form 10-Q Financial Statement

#000165495421009097 Filed on August 16, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTO
Entero Therapeutics Inc Stock $ento